Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Aging Cell ; 15(3): 582-4, 2016 06.
Article in English | MEDLINE | ID: mdl-27139744

ABSTRACT

Recent high-profile studies report GDF11 to be a key circulating 'anti-aging' factor. However, a screen of extracellular proteins attempting to identify factors with 'anti-aging' phenotypes in aged murine skeletal muscle satellite cells did not identify GDF11 activity. We have been unable to confirm the reported activity of GDF11, similar to other laboratories offering conflicting data and describe our attempts to do so in this short take.


Subject(s)
Cellular Senescence/drug effects , Growth Differentiation Factors/pharmacology , Satellite Cells, Skeletal Muscle/cytology , Animals , Cell Count , HEK293 Cells , Humans , Mice , Recombinant Proteins/pharmacology , Satellite Cells, Skeletal Muscle/drug effects , Satellite Cells, Skeletal Muscle/metabolism
2.
ACS Chem Biol ; 11(2): 518-29, 2016 Feb 19.
Article in English | MEDLINE | ID: mdl-26696218

ABSTRACT

Skeletal muscle progenitor stem cells (referred to as satellite cells) represent the primary pool of stem cells in adult skeletal muscle responsible for the generation of new skeletal muscle in response to injury. Satellite cells derived from aged muscle display a significant reduction in regenerative capacity to form functional muscle. This decrease in functional recovery has been attributed to a decrease in proliferative capacity of satellite cells. Hence, agents that enhance the proliferative abilities of satellite cells may hold promise as therapies for a variety of pathological settings, including repair of injured muscle and age- or disease-associated muscle wasting. Through phenotypic screening of isolated murine satellite cells, we identified a series of 2,4-diaminopyrimidines (e.g., 2) that increased satellite cell proliferation. Importantly, compound 2 was effective in accelerating repair of damaged skeletal muscle in an in vivo mouse model of skeletal muscle injury. While these compounds were originally prepared as c-Jun N-terminal kinase 1 (JNK-1) inhibitors, structure-activity analyses indicated JNK-1 inhibition does not correlate with satellite cell activity. Screening against a broad panel of kinases did not result in identification of an obvious molecular target, so we conducted cell-based proteomics experiments in an attempt to identify the molecular target(s) responsible for the potentiation of the satellite cell proliferation. These data provide the foundation for future efforts to design improved small molecules as potential therapeutics for muscle repair and regeneration.


Subject(s)
Cell Proliferation/drug effects , Muscle, Skeletal/drug effects , Muscle, Skeletal/physiology , Pyrimidines/chemistry , Pyrimidines/pharmacology , Regeneration/drug effects , 3T3 Cells , Animals , Cells, Cultured , Drug Discovery , Humans , Mice , Muscle, Skeletal/cytology , Muscle, Skeletal/injuries , Pyrimidines/pharmacokinetics , Stem Cells/cytology , Stem Cells/drug effects
3.
PLoS One ; 9(2): e90398, 2014.
Article in English | MEDLINE | ID: mdl-24587351

ABSTRACT

Satellite cells are the chief contributor to skeletal muscle growth and regeneration. The study of mouse satellite cells has accelerated in recent years due to technical advancements in the isolation of these cells. The study of human satellite cells has lagged and thus little is known about how the biology of mouse and human satellite cells compare. We developed a flow cytometry-based method to prospectively isolate human skeletal muscle progenitors from the satellite cell pool using positive and negative selection markers. Results show that this pool is enriched in PAX7 expressing cells that possess robust myogenic potential including the ability to give rise to de novo muscle in vivo. We compared mouse and human satellite cells in culture and identify differences in the elaboration of the myogenic genetic program and in the sensitivity of the cells to cytokine stimulation. These results indicate that not all mechanisms regulating mouse satellite cell activation are conserved in human satellite cells and that such differences may impact the clinical translation of therapeutics validated in mouse models. Thus, the findings of this study are relevant to developing therapies to combat muscle disease.


Subject(s)
Muscle Development/genetics , Muscle, Skeletal/metabolism , Satellite Cells, Skeletal Muscle/metabolism , Adolescent , Adult , Animals , Biomarkers/metabolism , Female , Flow Cytometry , Gene Expression , Humans , Male , Mice , Middle Aged , Muscle, Skeletal/cytology , Muscle, Skeletal/growth & development , MyoD Protein/genetics , MyoD Protein/metabolism , Myogenic Regulatory Factor 5/genetics , Myogenic Regulatory Factor 5/metabolism , PAX7 Transcription Factor/genetics , PAX7 Transcription Factor/metabolism , Satellite Cells, Skeletal Muscle/cytology , Species Specificity
4.
J Med Chem ; 53(11): 4531-44, 2010 Jun 10.
Article in English | MEDLINE | ID: mdl-20469868

ABSTRACT

Glucocorticoid receptor (GR) agonists have been used for more than half a century as the most effective treatment of acute and chronic inflammatory conditions despite serious side effects that accompany their extended use that include glucose intolerance, muscle wasting, skin thinning, and osteoporosis. As a starting point for the identification of GR ligands with an improved therapeutic index, we wished to discover selective nonsteroidal GR agonists and antagonists with simplified structure compared to known GR ligands to serve as starting points for the optimization of dissociated GR modulators. To do so, we selected multiple chemical series by structure guided docking studies and evaluated GR agonist activity. From these efforts we identified 5-arylindazole compounds that showed moderate binding to the glucocorticoid receptor (GR) with clear opportunities for further development. Structure guided optimization was used to design arrays that led to potent GR agonists and antagonists. Several in vitro and in vivo experiments were utilized to demonstrate that GR agonist 23a (GSK9027) had a profile similar to that of a classical steroidal GR agonist.


Subject(s)
Drug Design , Indazoles/chemistry , Indazoles/pharmacology , Receptors, Glucocorticoid/agonists , Receptors, Glucocorticoid/antagonists & inhibitors , Animals , Dose-Response Relationship, Drug , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Indazoles/chemical synthesis , Indazoles/pharmacokinetics , Male , Mice , Models, Molecular , NF-kappa B/metabolism , Protein Conformation , Rats , Receptors, Glucocorticoid/chemistry , Receptors, Glucocorticoid/metabolism , Substrate Specificity
5.
Mol Endocrinol ; 24(2): 299-309, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19965931

ABSTRACT

Energy production by oxidative metabolism in kidney, stomach, and heart, is primarily expended in establishing ion gradients to drive renal electrolyte homeostasis, gastric acid secretion, and cardiac muscle contraction, respectively. In addition to orchestrating transcriptional control of oxidative metabolism, the orphan nuclear receptor, estrogen-related receptor gamma (ERRgamma), coordinates expression of genes central to ion homeostasis in oxidative tissues. Renal, gastric, and cardiac tissues subjected to genomic analysis of expression in perinatal ERRgamma null mice revealed a characteristic dysregulation of genes involved in transport processes, exemplified by the voltage-gated potassium channel, Kcne2. Consistently, ERRgamma null animals die during the first 72 h of life with elevated serum potassium, reductions in key gastric acid production markers, and cardiac arrhythmia with prolonged QT intervals. In addition, we find altered expression of several genes associated with hypertension in ERRgamma null mice. These findings suggest a potential role for genetic polymorphisms at the ERRgamma locus and ERRgamma modulators in the etiology and treatment of renal, gastric, and cardiac dysfunction.


Subject(s)
Gastric Mucosa/metabolism , Gene Expression Regulation , Heart/physiology , Kidney/metabolism , Myocardium/metabolism , Potassium/metabolism , Receptors, Estrogen/physiology , Adult , Animals , Animals, Newborn , Body Mass Index , Female , Genetic Association Studies , Homeostasis , Humans , Hypertension/genetics , Kidney/pathology , Long QT Syndrome/genetics , Male , Mice , Middle Aged , Myocardium/pathology , Oligonucleotide Array Sequence Analysis , Organ Specificity , Polymorphism, Single Nucleotide , Potassium Channels, Voltage-Gated/genetics , Potassium Channels, Voltage-Gated/metabolism , Receptors, Estrogen/deficiency , Receptors, Estrogen/genetics , Stomach/pathology
7.
J Biol Chem ; 280(35): 31283-93, 2005 Sep 02.
Article in English | MEDLINE | ID: mdl-15967794

ABSTRACT

Ligand binding is the first step in hormone regulation of mineralocorticoid receptor (MR) activity. Here, we report multiple crystal structures of MR (NR3C2) bound to both agonist and antagonists. These structures combined with mutagenesis studies reveal that maximal receptor activation involves an intricate ligand-mediated hydrogen bond network with Asn770 which serves dual roles: stabilization of the loop preceding the C-terminal activation function-2 helix and direct contact with the hormone ligand. In addition, most activating ligands hydrogen bond to Thr945 on helix 10. Structural characterization of the naturally occurring S810L mutant explains how stabilization of a helix 3/helix 5 interaction can circumvent the requirement for this hydrogen bond network. Taken together, these results explain the potency of MR activation by aldosterone, the weak activation induced by progesterone and the antihypertensive agent spironolactone, and the binding selectivity of cortisol over cortisone.


Subject(s)
Hydrogen Bonding , Protein Structure, Tertiary , Receptors, Mineralocorticoid/chemistry , Receptors, Mineralocorticoid/metabolism , Crystallography, X-Ray , Humans , Ligands , Models, Molecular , Molecular Structure , Mutation , Protein Binding , Protein Structure, Secondary , Receptors, Mineralocorticoid/genetics , Steroids/chemistry , Steroids/metabolism , Transcriptional Activation
8.
BMC Bioinformatics ; 5: 173, 2004 Oct 29.
Article in English | MEDLINE | ID: mdl-15516260

ABSTRACT

BACKGROUND: The program InDeVal was originally developed to help researchers find known regions of insertion/deletion activity (with the exception of isolated single-base indels) in newly determined Poaceae trnL-F sequences and compare them with 533 previously determined sequences. It is supplied with input files designed for this purpose. More broadly, the program is applicable for finding specific target regions (referred to as "variable regions") in DNA sequence. A variable region is any specific sequence fragment of interest, such as an indel region, a codon or codons, or sequence coding for a particular RNA secondary structure. RESULTS: InDeVal input is DNA sequence and a template file (sequence flanking each variable region). Additional files contain the variable regions and user-defined messages about the sequence found within them (e.g., taxa sharing each of the different indel patterns).Variable regions are found by determining the position of flanking sequence (referred to as "conserved regions") using the LPAM (Length-Preserving Alignment Method) algorithm. This algorithm was designed for InDeVal and is described here for the first time. InDeVal output is an interactive display of the analyzed sequence, broken into user-defined units. Once the user is satisfied with the organization of the display, the information can be exported to an annotated text file. CONCLUSIONS: InDeVal can find multiple variable regions simultaneously (28 indel regions in the Poaceae trnL-F files) and display user-selected messages specific to the sequence variants found. InDeVal output is designed to facilitate comparison between the analyzed sequence and previously evaluated sequence. The program's sensitivity to different levels of nucleotide and/or length variation in conserved regions can be adjusted. InDeVal is currently available for Windows in Additional file 1 or from http://www.sci.muni.cz/botany/elzdroje/indeval/.


Subject(s)
DNA Mutational Analysis/methods , DNA, Plant/genetics , Mutagenesis, Insertional/genetics , Sequence Deletion/genetics , Software , Codon/genetics , Conserved Sequence/genetics , Poaceae/genetics , Sequence Alignment/methods
9.
Biochemistry ; 42(31): 9278-87, 2003 Aug 12.
Article in English | MEDLINE | ID: mdl-12899614

ABSTRACT

Natural ligands for nuclear receptors are believed to activate gene transcription by causing dissociation of corepressors and promoting the association of coactivator proteins. Using multiple biophysical techniques, we find that peptides derived from one of the nuclear receptor interacting motifs of the corepressors nuclear receptor corepressor (NCoR) and silencing mediator of retinoid and thyroid receptors (SMRT) are able to bind the ligand binding domains (LBD) of all three PPAR (peroxisome proliferator activated receptor) subtypes. Using these peptides as tools, we find that ligands designed as selective agonists for PPAR gamma promote the association of coactivator peptides and dissociation of corepressor peptides as expected on PPAR gamma but surprisingly have varied effects on the binding of corepressor peptides to the other PPAR subtypes. In particular, some members of a class of L-tyrosine-based compounds designed as selective agonists for PPAR gamma reduce the affinity for corepressor peptides on PPAR gamma but increase the affinity for the same peptides on PPAR delta and in one case on PPAR alpha. We provide structural data that suggests that the molecular basis for these observations are variations in the ligand binding pockets of the three PPAR subtypes that are perturbed differentially by individual ligands and result in altered presentations of the overlapping coactivator/corepressor binding surfaces.


Subject(s)
DNA-Binding Proteins/metabolism , Nuclear Proteins/metabolism , Oxazoles/chemistry , Receptors, Cytoplasmic and Nuclear/metabolism , Repressor Proteins/metabolism , Transcription Factors/metabolism , Amino Acid Motifs , Binding Sites , Cells, Cultured , Crystallography, X-Ray , Fluorescence , Humans , Ligands , Models, Molecular , Molecular Structure , Nuclear Receptor Co-Repressor 1 , Nuclear Receptor Co-Repressor 2 , Oxazoles/pharmacology , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Protein Isoforms , Protein Structure, Tertiary , Receptors, Cytoplasmic and Nuclear/agonists , Transcription Factors/agonists , Transfection , Two-Hybrid System Techniques , Tyrosine/analogs & derivatives , Tyrosine/metabolism
10.
Genes Dev ; 17(13): 1581-91, 2003 Jul 01.
Article in English | MEDLINE | ID: mdl-12815072

ABSTRACT

The nuclear bile acid receptor FXR has been proposed to play a central role in the feedback repression of the gene encoding cholesterol 7 alpha-hydroxylase (CYP7A1), the first and rate-limiting step in the biosynthesis of bile acids. We demonstrate that FXR directly regulates expression of fibroblast growth factor-19 (FGF-19), a secreted growth factor that signals through the FGFR4 cell-surface receptor tyrosine kinase. In turn, FGF-19 strongly suppresses expression of CYP7A1 in primary cultures of human hepatocytes and mouse liver through a c-Jun N-terminal kinase (JNK)-dependent pathway. This signaling cascade defines a novel mechanism for feedback repression of bile acid biosynthesis and underscores the vital role of FXR in the regulation of multiple pathways of cholesterol catabolism in the liver.


Subject(s)
Bile Acids and Salts/biosynthesis , Cholesterol 7-alpha-Hydroxylase/genetics , DNA-Binding Proteins/metabolism , Fibroblast Growth Factors/metabolism , Hepatocytes/metabolism , Signal Transduction , Transcription Factors/metabolism , Animals , Anthracenes/pharmacology , Cell Line , Cells, Cultured , Chenodeoxycholic Acid/pharmacology , Cholesterol 7-alpha-Hydroxylase/metabolism , DNA-Binding Proteins/agonists , DNA-Binding Proteins/genetics , Enzyme Repression , Fibroblast Growth Factors/genetics , Fibroblast Growth Factors/pharmacology , Gene Expression Regulation , Humans , Isoxazoles/pharmacology , JNK Mitogen-Activated Protein Kinases , Mice , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinases/metabolism , Phosphorylation , Proto-Oncogene Proteins c-jun/metabolism , Receptors, Cytoplasmic and Nuclear , Recombinant Proteins/pharmacology , Response Elements , Transcription Factors/agonists , Transcription Factors/genetics , Transfection
11.
Mol Endocrinol ; 17(9): 1704-14, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12817079

ABSTRACT

The ligand-binding domain (LBD) of apo-nuclear receptors in solution is thought to be a very dynamic structure with many possible conformations. Upon ligand binding, the structure is stabilized to a more rigid conformation. The dynamic stabilization assay is a LBD reassembly assay that takes advantage of the high specificity of the intramolecular interactions that comprise the ligand-bound LBD. Here, we demonstrate dynamic stabilization for the nuclear receptors peroxisome proliferator-activated receptor (PPAR)gamma and nerve growth factor inducible (NGFIB)beta and identify residues important for stabilization of the intramolecular interactions induced by PPARgamma ligands. Site-directed mutagenesis studies identified residues in helices 1 and 8 required for LBD reassembly. Further, disrupting the helix 1/8 interaction in the context of the holo-LBD alters the response of the receptor in a compound-specific manner, suggesting that residues far from the ligand-binding pocket can influence the stability of the ligand-bound receptor. Thus, these results support and extend models of the apo-LBD of PPARgamma as a dynamic structure.


Subject(s)
DNA-Binding Proteins/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Transcription Factors/metabolism , DNA-Binding Proteins/genetics , Ligands , Mutation , Nuclear Receptor Subfamily 4, Group A, Member 1 , Protein Binding , Protein Structure, Secondary , Protein Structure, Tertiary , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Steroid , Transcription Factors/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...